GSK's sales in China improving

|By:, SA News Editor

GlaxoSmithKline's (GSK +1%) sales in China have been recovering since Q3, when revenue plummeted 61% following the emergence of accusations that the company bribed doctors.

"The trend is definitely looking a bit more positive," says CFO Simon Dingemans. "We can see the future opportunities to rebuild the business as and when we get to the other side of the (bribery) inquiry."

Meanwhile, a study from the Centers for Disease Control & Prevention has found that GSK's Rotarix vaccine for preventing severe diarrhea in infants could slightly increase the risk of bowel blockage. However, the problem isn't severe enough to warrant a change in recommendation for the vaccine's use.

An FDA report on Merck's (MRK -1%) RotaTeq has come to a similar conclusion.